Floatz logo

Zotiraciclib

Anaplastic Astrocytoma

European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
gsk1120212
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Zotiraciclib is also rated in:

astrocytic tumorDormant
CC
Indicative ·
42 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CC
Indicative ·
41 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →